Correction: Thyroid peroxidase antibodies in bipolar disorder: implications for clinical sub-phenotypes and lithium response (International Journal of Bipolar Disorders, (2026), 14, 1, (20), 10.1186/s40345-026-00419-9)

In Table 1 of the article (Pathak et al. 2026), in the rows labeled “Lithium Alda-A score” and “Lithium Alda response,” the values provided in the ‘TPO-positive,’ ‘TPO-negative,’ and ‘all cases’ columns appear to be shifted upward by one row. The table has been updated with the values corresponding to the correct rows for your review. The Table should have appeared as shown below. The original article has been corrected. Demographic and clinical characteristics of participants by thyroid peroxidase antibody (TPO-Ab) status Variables TPO-Ab positive cases (N = 81) TPO-Ab negative cases (N = 258) All cases (N = 339) P value Age (years) 43.8 (13.7) 43.8 (15.7) 43.8 (15.2) 0.974 Sex • Female • Male 56 (69.1) 25 (30.9) 151 (58.5) 107 (41.5) 207 (61.1) 132 (38.9) 0.088 Race (n = 334) • White • Black • Asian • Multiracial • Other 74 (92.5) 2 (2.5) 0 (0.0) 3 (3.8) 1 (1.2) 236 (92.9) 1 (0.4) 3 (1.2) 12 (4.7) 2 (0.8) 310 (92.8) 3 (0.9) 3 (0.9) 15 (4.5) 3 (0.9) 0.376 BMI (kg/m²) (n = 322) 31.7 (7.9) 29.9 (7.0) 30.3 (7.3) 0.059 Marital status (n = 338) • No • Yes 32 (39.5) 49 (60.5) 119 (46.3) 138 (53.7) 151 (44.7) 187 (55.3) 0.283 Education (n = 325) • HS or below • Above HS 12 (15.4) 66 (84.6) 33 (13.4) 214 (86.6) 45 (13.8) 280 (86.2) 0.652 Employment status (n = 321) • Unemployed • Employed (full-time) • Employed (part-time) 39 (50.6) 20 (26.0) 18 (23.4) 129 (52.9) 67 (27.5) 48 (19.7) 168 (52.3) 87 (27.1) 66 (20.6) 0.781 History of tobacco use (n = 325) • No • Yes 40 (51.3) 38 (48.7) 122 (49.4) 125 (50.6) 162 (49.8) 163 (50.2) 0.771 Diagnosis • Bipolar I • Bipolar II 49 (60.5) 32 (39.5) 176 (68.2) 82 (31.8) 225 (66.4) 114 (33.6) 0.199 Age at BD diagnosis (n = 303) • ≤ 19 years • > 19 years 27 (39.1) 42 (60.9) 77 (32.9) 157 (67.1) 104 (34.3) 199 (65.7) 0.339 Comorbidities • ADHD (n = 332) • Anxiety disorders (n = 334) • Eating disorders (n = 332) • ≥ 1 autoimmune disorders (n = 121) 12 (15.6) 50 (64.1) 9 (11.5) 8 (17.8) 54 (21.2) 150 (58.6) 34 (13.4) 12 (15.8) 66 (19.9) 200 (59.9) 43 (13.0) 20 (16.5) 0.281 0.385 0.671 0.776 History of psychosis (mania, depression, or euthymia) (n = 336) 21 (25.9) 102 (40.0) 123 (36.6) History of rapid cycling (n = 272) 25 (48.1) 112 (50.9) 137 (50.4) 0.713 History of ≥ 1 suicide attempt (n = 338) 30 (37.0) 68 (26.5) 98 (29.0) 0.067 History of lithium treatment (n = 296) 48 (72.7) 165 (71.7) 213 (72.0) 0.875 Current mood stabilizers • Lithium (n = 253) • Valproate (n = 216) • Lamotrigine (n = 238) 35 (60.3) 9 (15.3) 26 (42.6) 141 (72.3) 37 (23.6) 75 (42.4) 176 (69.6) 46 (21.3) 101 (42.4) 0.082 0.184 0.973 Lithium treatment response (n = 160) • Lithium Alda-A score 5.8 (2.7) 6.7 (2.0) 6.5 (2.2) 0.067 • Lithium Alda response ✓ Good (score ≥ 7) ✓ Moderate (score 4–6) ✓ Poor (score ≤ 3) 19 (48.7) 12 (30.8) 8 (20.5) 67 (55.4) 48 (39.7) 6 (5.0) 86 (53.8) 60 (37.5) 14 (8.8) History of AIM (n = 248) 8 (11.9) 38 (21.0) 46 (18.5)